Preparation and Characterization of a Polyclonal Antibody against Brominated Protein by Kambayashi, Yasuhiro et al.
95
Original Article J. Clin. Biochem. Nutr., 44, 95–103, January 2009
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn08-196 10.3164/jcbn.08-196 Original Article Preparation and Characterization of a Polyclonal Antibody against 
Brominated Protein
Yasuhiro Kambayashi1, Keiki Ogino2,*, Kei Takemoto2, Takashi Imagama3, Tomoko Takigawa2, 
Shingo Kimura1, Yuri Hibino1, Yoshiaki Hitomi1, and Hiroyuki Nakamura1
1Department of Environmental and Preventive Medicine, Graduate School of Medical Science, 
Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8640, Japan
2Department of Public Health, Okayama University Graduate School of Medicine, Density, 
and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
3Department of Orthopedic Surgery, Yamaguchi School of Medicine, 1-1-1 Minami-Kogushi, Ube 755-8505, Japan
1 2009 ?? 12 2009 44 1 95 103 Received 24.7.2008 ; accepted 26.9.2008
*To whom correspondence should be addressed.    
Tel: +81 86 235 7184    Fax: +81 86 226 0715    
E-mail: kogino@md.okayama-u.ac.jp
Received 24 July, 2008; Accepted 26 September, 2008
Copyright © 2009 JCBN Summary (Di)bromotyrosine is formed by the specific reaction of eosinophil peroxidase and
can be used as an eosinophil activation marker. In the present study, an antibody for
(di)bromotyrosine in proteins was prepared to investigate the pathogenesis of eosinophil-
related diseases such as allergic responses. A rabbit polyclonal antibody was raised against
brominated keyhole limpet hemocyanin. The specificity of the antiserum was investigated with
an enzyme-linked immunosorbent assay (ELISA). The antiserum recognized brominated
bovine serum albumin (BSA) and dibromotyrosine-conjugated BSA. The antiserum also
reacted with chlorinated BSA and di-iodotyrosine-conjugated BSA. Moreover, the specificity
of the antiserum was investigated using competitive ELISA. Dibromotyrosine and di-
iodotyrosine inhibited the recognition of brominated BSA by the antiserum. However, the
recognition of brominated BSA by the antiserum was not inhibited by bromotyrosine, chloro-
tyrosine, iodotyrosine, nitrotyrosine, aminotyrosine, phosphotyrosine, or tyrosine. These results
suggested that the epitope of the antiserum is dihalogenated tyrosine. Immunohistochemically,
the antiserum stained brominated rat eosinophils but not chlorinated or nitrated eosinophils.
In conclusion, an antiserum for dihalogenated protein was prepared. It is expected that the
antiserum will be useful for the analysis of the pathogenesis of allergic diseases such as asthma
and atopic dermatitis.
Key Words:(di)bromotyrosine, eosinophil activation marker, polyclonal antibody, 
allergic disease, oxidative stress
Introduction
Eosinophils play a pivotal role in host defense, such as in
killing invasive parasites [1]. Eosinophils are also involved
in the pathophysiology of allergic diseases [1–5]. When
eosinophils are activated, eosinophil-specific granule pro-
teins (eosinophil peroxidase (EPO), major basic protein,
eosinophil cationic protein, and eosinophil-derived neuro-
toxin) are released and proceed to induce tissue damage.
Halogenated tyrosine is formed by the specific reaction of
myeloperoxidase (MPO), a neutrophil specific enzyme [6–8],
and EPO [9]. MPO prefers chloride (Cl−) to bromide (Br−) as
a substrate and produces hypochlorous acid (HOCl) (equa-
tion 1) [2, 10–14]. In contrast, EPO prefers Br− to Cl− as a
substrate and produces hypobromous acid (HOBr) (equationY. Kambayashi et al.
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2) [2, 9, 13, 15]. HOCl and HOBr halogenate tyrosine (Tyr)
residues and produce chlorotyrosine (Cl-Tyr) and bromoty-
rosine (Br-Tyr), respectively (equation 3). Dibromotyrosine
(diBr-Tyr) is also formed by the bromination of Br-Tyr by
HOBr (equation 4). When EPO is activated, both Br-Tyr and
diBr-Tyr are formed.
MPO + H2O2 +C l − → HOCl (1)
EPO + H2O2 +B r − → HOBr (2)
Tyr + HOCl (HOBr) → Cl-Tyr (Br-Tyr) (3)
Br-Tyr + HOBr → diBr-Tyr (4)
Several reports indicate that both EPO and MPO produce
HOCl and HOBr in vitro [16–19]. However, a study using
EPO-knockout mice and MPO-knockout mice showed clearly
that the source of Br-Tyr is EPO, and that of Cl-Tyr is MPO
in vivo [20]. Therefore, (di)Br-Tyr is expected to be useable
as a marker for eosinophil activation in vivo [9]. In fact,
high levels of Br-Tyr in the urine, endotracheal/bronchial
aspirate, and sputum of asthma patients have been reported
[2, 21, 22]. In these reports, bromotyrosine was measured by
gas chromatography/mass spectrometry. If an antibody for
(di)Br-Tyr is obtained, it will be useful for investigation of
the pathogenesis of eosinophil-related allergic diseases such
as asthma and atopic dermatitis. Thus, this study attempted
to prepare a specific polyclonal antibody for (di)Br-Tyr.
Materials and Methods
Reagents
Bovine serum albumin (BSA), Tyr, 3,5-diiode-L-tyrosine
(diI-Tyr) dihydrate, 3-nitro-L-tyrosine (NO2-Tyr), Cl-Tyr
hydrochloride, and O-phospho-L-tyrosine (P-Tyr) were
purchased from Sigma Chemical Co. (St. Louis, MO). 3-
Amino-L-tyrosine (NH2-Tyr) dihydrochloride, iodotyrosine
(I-Tyr), and 3-chloro-4-hydroxybenzoic acid (Cl-HBA)
were from Aldrich Chemical Company, Inc. (Milwaukee,
WI). 3,5-Dibromo-L-tyrosine (diBr-Tyr), 3,5-dibromo-4-
hydroxybenzoic acid (diBr-HBA), 3,5-dichloro-4-
hydroxybenzoic acid (diCl-HBA), 3-nitro-4-hydroxybenzoic
acid (NO2-HBA), and 3-amino-4-hydroxybenzoic acid
(NH2-HBA) were from Tokyo Kasei Kogyo Co. Ltd. (Tokyo,
Japan). 3-Bromo-4-hydroxybenzoic acid (Br-HBA), sodium
hypochlorite, hydrogen peroxide (H2O2), and normal goat
serum were obtained from Wako Pure Chemical Industries,
Ltd. (Osaka, Japan). 3,5-Dinitro-4-hyrdroyxybenzoic acid
(diNO2-HBA) was from AVOCADO Research Chemicals,
Ltd. (Lancashire, UK). Peroxynitrite, diethylenetriamine-
N,N,N',N'',N''-pentaacetic acid (DTPA), and N-(6-
maleimidocaproyloxy)-succinimide (EMCS) were from
Dojindo Laboratories (Kumamoto, Japan). Imject® maricul-
ture keyhole limpet hemocyanin (KLH), Freund’s complete
adjuvant, Freund’s incomplete adjuvant, N-succinimidyl 3-
(2-pyridyldithio)propionate  (SPDP), and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC)
were from PIERCE Biotechnology, Inc. (Rockford, IL,
USA). Sodium hypobromite was from Kanto Chemical Co.,
Ltd. (Tokyo, Japan). Solvents and other reagents were of the
highest grade commercially available. The absorbance of
hypochlorite and hypobromite were measured spectrophoto-
metrically and their concentrations were calculated from
their molar extinction coefficients (ε292nm = 350 M−1cm−1
[23] and ε331nm =3 1 5M −1cm−1 [ 24], respectively). Br-Tyr
was prepared by the bromination of Tyr using sodium
hypobromite and purified by high performance liquid
chromatography (HPLC).
Animals
Japanese white rabbits were purchased from Kiwa
Laboratory Animals Co., Ltd. (Wakayama, Japan). Wistar
rats were purchased from Shiroishi Lab. Animal Reproduc-
tion Inc. (Tokyo, Japan). The care and handling of the
animals were in accordance with the Guidelines for the Care
and Use of Laboratory Animals of Kanazawa University.
Preparation of modified protein
One millimolar sodium hypobromite or 5 mM sodium
hypochlorite was added to 5 mg/ml BSA or KLH at room
temperature. After dialysis with 10 mM phosphate-buffered
saline (pH 7.2), a part of the modified protein was digested
with pronase (Roche Diagnostics, Basel, Switzerland). Br-
Tyr and Cl-Tyr were analyzed by HPLC to confirm the
bromination and chlorination, respectively, of tyrosine in the
proteins. Water/methanol/acetic acid (= 97/3/0.1, v/v/v) and
a CAPCELPAK C18 column (4.6 × 250 mm, 5 µm, Shiseido
Co., Ltd., Tokyo, Japan) were used as the mobile phase
and column, respectively. DiBr-Tyr was analyzed by HPLC
to confirm the dibromination of tyrosine in the proteins.
Water/methanol/acetic acid (= 80/20/0.1, v/v/v) and a
CAPCELPAK C18 column (4.6 × 250 mm, 5 μm, Shiseido
Co., Ltd., Tokyo, Japan) were used as the mobile phase and
column, respectively. Modified tyrosine was detected at
274 nm. Nitrated BSA was prepared by the reaction of
5 mg/ml BSA with 1 mM peroxynitrite. Tyr or modified Tyr
was conjugated with BSA using SPDP and EMCS as
reported previously [25]. Modified hydroxybenzoic acid
(HBA) was conjugated with BSA using EDC as reported
previously [26]. After dialysis, the concentrations of the
modified BSAs were determined by the Bradford protein
quantitation assay (Bio-Rad Laboratories, Hercules, CA).
Immunization
Brominated KLH (500 μg) as an immunogen in 2 ml of
10 mM phosphate-buffered saline (pH 7.2) was mixed with
4 ml of Freund’s complete adjuvant (first injection) or
Freund’s incomplete adjuvant (booster injections). Arterial
blood was drawn from the ear of the rabbit before the
administration of the immunogen subcutaneously at 2 weekAntibody for Brominated Protein
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intervals. The titer of the antiserum was examined using an
enzyme-linked immunosorbent assay (ELISA).
ELISA
Five hundred nanograms of antigen dissolved in 60 mM
carbonate buffer (pH 9.6) was added to each well of a 96
well microplate and incubated at 4°C overnight. Three
percent skim milk in 10 mM Tris-buffered saline was used
for the blocking of non-specific binding. The rabbit anti-
serum (1:3,000) was used as a primary antibody and
horseradish peroxidase-conjugated goat anti-rabbit-
immunoglobulin (1:2,000, Dako Cytomation, Glostrup,
Denmark) as a secondary antibody. Visualization was
performed using a Colorimetric kit T (Sumitomo Bakelite
Co., Ltd., Tokyo, Japan). The absorbance at 450 nm was
measured using a microplate reader. When competitive
ELISA was performed, the antiserum was preincubated
with competitor for 2 h. The pH of each competitor solution
was adjusted to 7.4 before addition to the antiserum.
Immunohistochemistry
Horse serum was injected intraperitoneally into a rat
every 3 days [27]. At 24 h after the third injection, peritoneal
exudate cells were collected by washing the abdominal
cavity with Hanks’ balanced salt solution. On a cytospin
slide (2 × 105 cells), rat eosinophils were stained with Luxol
fast blue. The cytospin slides (with eosinophil-containing
cells) were incubated with 100 μM sodium bromide,
140 mM sodium chloride, or 50 μM sodium nitrite in the
presence of 100 μM DTPA plus 100 μM H2O2 in 50 mM
potassium phosphate buffer (pH 7.4) for 5 min at 37°C.
Control specimens were incubated with 100 μM DTPA or
100 μM DTPA plus 100 μM H2O2. Cells were fixed with
10% formalin. Endogenous peroxidase activity was blocked
with 0.3% H2O2-containing methanol. Five percent normal
goat serum was used to block non-specific binding. The
rabbit antiserum (1:4,000) was incubated with specimens
at 4°C overnight. As a secondary antibody, anti-rabbit
immunoglobulin antibody with horseradish peroxidase-
labeled dextran polymer (1:16, Dako Cytomation) was
used. Staining was performed by the reaction with 3,3'-
diaminobenzidine tetrahydrochloride and H2O2. The cells
were counterstained with hematoxylin.
Statistical analysis
Statistical analysis of the differences in the mean values
was performed by two-way analysis of variance (ANOVA)
and one-way ANOVA, followed by the Tukey’s post hoc
test using SPSS 11.5 software (SPSS, Chicago, IL).
Results
Synthesis of the immunogen and antigens
KLH was brominated using HOBr (Fig. 1a). An analytical
method for various modified Tyr residues using HPLC was
developed to confirm the bromination of Tyr in brominated
KLH. The retention times of Tyr, Cl-Tyr, Br-Tyr, and NO2-
Tyr were 5.9, 14.9, 20.1, and 20.9 min, respectively
(Fig. 2A). Another analytical method for diBr-Tyr (retention
time: 11.1 min) was also developed (Fig. 2C). Using these
methods, the pronase hydrolysate of brominated KLH was
analyzed (Fig. 2B and D). Br-Tyr and diBr-Tyr were formed
in KLH but Cl-Tyr and NO2-Tyr were not observed in the
hydrolysate. Therefore, brominated KLH was used as the
immunogen. Modified BSA, modified Tyr-conjugated BSA
and modified HBA-conjugated BSA as antigens for ELISA
were synthesized as described in the “Materials and
Methods” section (Fig. 1a–c).
Characteristics of the antiserum: ELISA
Rabbit antiserum raised against brominated KLH was
obtained, and the reactivity of the antiserum was investi-
gated using ELISA (Fig. 3A). The recognition of bromi-
nated BSA by the antiserum (1:3,000) was proportional to
the antigen concentrations and reached a plateau at 500 ng/
well. In contrast, the antiserum did not recognize BSA. The
titer of the antiserum was examined (Fig. 3B). The recogni-
tion of brominated BSA by the antiserum was inversely
proportional to the dilution ratio of the antiserum. When a
high concentration of antiserum was used, it recognized
BSA very weakly. However, when 3,000-fold-diluted
antiserum was used, the recognition of BSA was negligible.
Thus, the optimum concentrations of the antigen and
antiserum for ELISA were determined to be 500 ng/well
and 1:3,000, respectively.
The antigen specificity of the antiserum was investigated
using various modified BSAs as antigens for ELISA
(Fig. 4). The antiserum recognized brominated BSA and
diBr-Tyr-conjugated BSA. However, it did not recognize
diBr-HBA-conjugated BSA. The antiserum reacted with
diI-Tyr-conjugated BSA and chlorinated BSA. Weak
recognition of Br-Tyr-conjugated BSA and Cl-Tyr-conjugated
BSA by the antiserum was observed, but its level was the
same as that of the recognition of Tyr-conjugated BSA
by the antiserum. NO2-Tyr can be formed in vivo via
peroxidase-catalyzed nitration of Tyr. NH2-Tyr was also
formed in vivo via the reduction of NO2-Tyr. The antiserum
weakly recognized NO2-Tyr-conjugated BSA and NH2-Tyr-
conjugated BSA, but it did not react with nitrated BSA,
Br-HBA-conjugated BSA, diCl-HBA-conjugate BSA, Cl-
HBA-conjugated BSA, NO2-HBA-conjugated BSA, NH2-
HBA-conjugated BSA, or BSA. These results suggest that
the antiserum recognized dihalogenated tyrosine.Y. Kambayashi et al.
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Characteristics of the antiserum: competitive ELISA
To further confirm the antigen specificity of the antiserum,
competitive ELISA was performed. When brominated BSA
was used as an antigen, diBr-Tyr and diI-Tyr inhibited the
recognition of the antigen by the antiserum (Fig. 5A). DiBr-
HBA also inhibited the recognition of brominated BSA by
the antiserum (Fig. 5C). Comparable results were obtained
when diBr-Tyr-conjugated BSA or chlorinated BSA was
used as antigen (data not shown).
Characteristics of the antiserum: Immunohistochemistry
The antiserum was applied for immunohistochemical
analysis. Part of a sample of rat peritoneal exudate cells was
stained with Luxol fast blue, which selectively stains
Fig. 1. Procedure for the synthesis of antigens. (A) Brominated KLH (BSA). (B) Modified Tyr-conjugated BSA. (C) Modified
HBA-conjugated BSA.
Fig. 2. HPLC analytical chromatograms of various modified Tyrs. (A, C) Standards. (B, D) Pronase hydrolysate of brominated KLH.
(A, B) Analytical method for various modified Tyr residues. (C, D) Analytical method for diBr-Tyr.Antibody for Brominated Protein
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eosinophil granules (Fig. 6A). These cells had ring-shaped
nuclei, which are characteristic of rat eosinophils (Fig. 6A).
The physiological concentrations of Br− and nitrite in the
plasma of healthy humans are 16–101 μM [28] and 0.1–
20 μM [29], respectively, and the concentration of Cl− in
saline is 137 mM. In the inflammatory state, the concentra-
tion of nitrite in the plasma increases. Therefore, 100 μM
Br−, 140 mM Cl−, or 50 μM nitrite was used to modify the
rat eosinophils. Control and H2O2-treated eosinophils were
not stained by the antiserum (Fig. 6B and C). This result
indicates that the antiserum does not recognize the oxidative
modification of tyrosine or other substrates. Brominated
eosinophils were stained by the antiserum (Fig. 6D),
whereas chlorinated cells and nitrated cells were not stained
(Fig. 6E and F, respectively). The nitration of eosinophils on
the slides by nitrite and H2O2 was confirmed by staining with
anti-NO2-Tyr polyclonal antibody (data not shown).
Discussion
The rabbit antiserum obtained in the present study
recognized diBr-Tyr in BSA. It reacted with diCl-Tyr in
BSA. However, the antiserum specifically detected HOBr-
modified protein of rat eosinophils in immunohisto-
chemistry. This difference can be explained at least in part
by the difference between the affinity of the antibody to
diBr-Tyr and that to diCl-Tyr, the steric hindrance in the
protein structure, the difference in protein species modified
by the two chemicals (HOBr and HOCl), and/or the
difference in the site of the tyrosine residues in a protein
modified by the two chemicals. The site-directed modifica-
tion of tyrosine (nitration, chlorination, bromination, oxida-
tion) has been reported previously [30–33].
The present results from the competitive ELISA indicate
that the affinity of the antiserum to diBr-Tyr and diI-Tyr was
Fig. 3. Characteristics of the antiserum. (A) Reactivity of the antiserum. Each well was coated with 5 to 500 ng/well antigen (brominated
BSA or BSA) and incubated with 3,000-fold-diluted antiserum. The results are expressed as mean ± standard deviation (n =3 ) .
Statistical analysis of the differences was performed by two-way ANOVA. Significant main effects of the concentration of
antigen (p<0.001) and the kind of antigen (p<0.001) and significant interactive effect between the concentration of antigen and
the kind of antigen (p<0.001) are shown. (B) Titer of the antiserum. Each well was coated with 500 ng/well antigen (brominated
BSA or BSA) and incubated with 1,000 to 100,000-fold-diluted antiserum. The results are expressed as mean ± standard
deviation (n = 3). Statistical analysis of the differences was performed by two-way ANOVA. Significant main effects of the
concentration of antigen (p<0.001) and the kind of antigen (p<0.001), and significant interactive effect between the concentra-
tion of antigen and the kind of antigen (p<0.001) are shown.
Fig. 4. The recognition of various modified tyrosines (Tyr) or
hydroxybenzoic acids (HBA) in BSA by the antiserum.
ELISA was performed to evaluate the specificity of the
antiserum. Each well was coated with 500 ng/well of
antigen and incubated with 3,000-fold-diluted antiserum.
The results are expressed as mean ± standard deviation
(n = 3). Statistical analysis of the differences was per-
formed by one-way ANOVA (p<0.001).Y. Kambayashi et al.
J. Clin. Biochem. Nutr.
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strongest. The antiserum strongly recognized brominated
BSA, diBr-Tyr-conjugated BSA, and diI-Tyr-conjugated
BSA but only weakly recognized Br-Tyr-conjugated BSA
and Cl-Tyr-conjugated BSA in the ELISA tests. DiNO2-Tyr
could not be recognized by the antiserum since diNO2-Tyr
was probably produced during nitration of BSA by
peroxynitrite and the antiserum did not recognize nitrated
BSA. Thus, the epitope recognized by the antiserum is likely
to be dihalogenated Tyr.
The antiserum weakly recognized NO2-Tyr-conjugated
BSA at a similar level to Tyr-conjugated BSA by ELISA.
Nitrated BSA was not recognized by the antiserum. These
results suggest that the antiserum could recognize the
tyrosine structure conjugated with the cross-linker but not
the intrinsic tyrosine structure in BSA. Probably, the anti-
serum recognized Br-Tyr-conjugated BSA, Cl-Tyr-conjugated
BSA, and NH2-Tyr-conjugated BSA by recognition of the
cross-linked Tyr structure. The recognition of brominated
BSA and chlorinated BSA by the antiserum showed that
the antiserum could recognize dihalogenation of intrinsic
tyrosine in protein.
The recognition of brominated BSA by the antiserum was
inhibited by diBr-HBA, but the antiserum did not recognize
diBr-HBA-conjugated BSA. The cause of this discrepancy
may be steric hindrance due to binding of diBr-HBA to the
cross-linker.
Several antibodies for halogenated tyrosine have been
reported [8,  34–36]. Monoclonal anti-Cl-Tyr antibody
(clone 2D10G9) raised against HOCl-modified low density
lipoprotein [34, 36] also recognized HOBr-treated BSA by
western blotting analysis [37]. Moreover, a monoclonal
antibody (clone 3A5) raised against N-bromosuccinimide-
modified KLH recognized diBr-Tyr-conjugated BSA and
HOCl-modified BSA as well as N-bromosuccinimide-
modified BSA by ELISA [35]. The recognition of diBr-Tyr-
conjugated BSA by the antibody was inhibited by various
(di)halogenated Tyrs and HBAs, such as diBr-Tyr, N-
acetylchlorotyrosine, diI-Tyr, diBr-HBA, diCl-HBA, and
Br-Tyr, using competitive ELISA [35]. The epitope of this
antibody was assumed to be dihalogenated Tyr and HBA
Fig. 5. Competitive ELISA using modified Tyrs and HBAs. The rabbit antiserum was preincubated with various concentrations of each
modified Tyr or modified HBA. Each well was coated with 500 ng/well of brominated BSA and incubated with 3,000-fold-
diluted antiserum. The results are expressed as the mean ± standard deviation (n = 3). Statistical analysis of the differences
was performed by two-way ANOVA. Significant main effects of the concentration of competitor (p<0.001) and the kind of
competitor (p<0.001) and interactive effect between the concentration of competitor and the kind of competitor (p<0.001) are
shown.Antibody for Brominated Protein
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[35]. Thus, the discrimination of each of the (di)halogenated
proteins by antibody may be difficult. Therefore, polyclonal
anti-Cl-Tyr antibody raised against Cl-HBA-conjugated
KLH [8] may also recognize various halogenated proteins,
such as brominated protein. Our antiserum raised against
HOBr-modified KLH also recognized various (di)haloge-
nated Tyr (but not halogenated HBA) using ELISA.
However, the antiserum specifically stained brominated rat
eosinophils using an immunohistochemical method. The
possibility that chlorination of rat eosinophils did not occur
could not be denied in the present study because confirma-
tion of the chlorination of rat eosinophils on a slide is
difficult. Although the antibodies reported for halogenated
tyrosine may recognize specific antigens immunohisto-
chemically, this point has not been investigated.
It may be difficult to produce a specific antibody for
(di)Br-Tyr in proteins because only one or two residues are
different between (di)Br-Tyr and other modified tyrosine
residues. In particular, the nature of one halogen is similar to
other halogens.
This study attempted to make a specific anti-Br-Tyr anti-
body by immunization of Br-Tyr-conjugated KLH or Br-
HBA-conjugated KLH into a rabbit, but this proved not to
be achievable. An antiserum that recognized diBr-Tyr was
successfully recovered when brominated KLH was used as
the immunogen. However, the antiserum did not recognize
Br-Tyr. A previously reported monoclonal antibody also
recognized dihalogenated BSA, but not Br-Tyr-conjugated
BSA [35]. Therefore, it may also be difficult to make an anti-
Br-Tyr antibody because of the probable weak characteristics
of Br-Tyr as an epitope.
The content of Br-Tyr and Cl-Tyr on proteins in
bronchoalveolar lavage fluid recovered from lung segments
of asthmatic subjects was increased by allergen-challenge
[38]. The levels of Br-Tyr and Cl-Tyr in the urine [22],
endotracheal/bronchial aspirate [2], and sputum [21] in
asthma patients were high. In these cases, diBr-Tyr and diCl-
Tyr could also be formed. In allergic diseases, activated
eosinophils could produce (di)Br-Tyr. Inflammation could
also occur in allergic diseases, neutrophils could be acti-
vated, and (di)Cl-Tyr may be formed. Therefore, the current
antiserum can be used for the analysis of the pathogenesis in
allergy diseases, although it was not a diBr-Tyr-specific
antiserum.
Acknowledgement
This work was supported in part by a Grant-in-Aid for
Scientific Research (C) 18590550 from the Ministry of
Education, Culture, Sports, Science and Technology of Japan.
Abbreviations
Br-HBA, bromohydroxybenzoic acid; Br-Tyr, bromoty-
rosine; Cl-HBA, chlorohydroxybenzoic acid; Cl-Tyr, chloro-
tyrosine;  diBr-HBA, dibromohydroxybenzoic acid; diBr-
Tyr, dibromotyrosine; diCl-HBA, dichlorohydroxybenzoic
acid; diBr-Tyr, dichlorotyrosine; DTPA, diethylenetriamine-
Fig. 6. Immunohistochemical staining of brominated protein in rat eosinophils. (A) Rat eosinophils were detected using Luxol fast blue
staining. (B-E) Chemically treated specimens (eosinophil-containing cells) were incubated with 4,000-fold-diluted rabbit
antiserum. (B) Control (100 µM DTPA). (C) B + 100 µM H2O2. (D) C + 100 µM Br−. (E) C + 140 mM Cl−. (F) C + 50 µM
nitrite. Scale bars represent 25 µm.Y. Kambayashi et al.
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N,N,N',N'',N''-pentaacetic acid; diNO2-HBA, dinitrohydroxy-
benzoic acid; diI-Tyr, di-iodotyrosine; EDC, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide-HCl; EMCS, N-(6-
maleimidocaproyloxy)-succinimide; EPO, eosinophil per-
oxidase; I-Tyr, iodotyrosine; HBA, hydroxybenzoic acid;
KLH, keyhole limpet hemocyanin; MPO, myeloperoxidase;
NH2-HBA, aminohydroxybenzoic acid; NH2-Tyr, amino-
tyrosine; NO2-HBA, nitrohydroxybenzoic acid; NO2-Tyr,
nitrotyrosine; P-Tyr, phosphotyrosine; SPDP, N-succinimidyl
3-(2-pyridyldithio)propionate; Tyr, tyrosine.
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